BidaskClub cut shares of R1 RCM (NASDAQ:RCM) from a strong-buy rating to a buy rating in a report published on Friday.
A number of other equities research analysts also recently issued reports on RCM. Robert W. Baird reissued a hold rating and set a $5.00 price target on shares of R1 RCM in a research report on Tuesday, September 26th. Zacks Investment Research raised R1 RCM from a strong sell rating to a hold rating in a research report on Wednesday, October 4th.
R1 RCM (NASDAQ RCM) traded up $0.03 during mid-day trading on Friday, reaching $4.22. The company’s stock had a trading volume of 221,200 shares, compared to its average volume of 245,600. R1 RCM has a 1 year low of $2.02 and a 1 year high of $4.64. The stock has a market capitalization of $437.92, a P/E ratio of -16.23 and a beta of -0.48.
ILLEGAL ACTIVITY WARNING: This news story was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.com-unik.info/2018/01/09/r1-rcm-rcm-downgraded-by-bidaskclub.html.
R1 RCM Company Profile
R1 RCM Inc, formerly Accretive Health, Inc, is a provider of revenue cycle management (RCM) and physician advisory services (PAS) to healthcare providers. The Company is engaged in providing management services of revenue cycle operations for the United States-based hospitals and other medical services providers.
What are top analysts saying about R1 RCM? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for R1 RCM and related companies.